Kirsten Axelson presents during the session titled “How Global Pricing Dynamics are Shaping Developer Market Access Strategies: Current and Future Trends” moderated by Rajini Jayasuriya.
For more information on this event, click here.
Keytruda and PD(L)1: Life after programmed death (part 2)
Looking ahead, we see a proliferation of PD-(L)1’s role; particularly in uses that go beyond traditional monoclonal, single-target antibodies (mAbs). Not only...